Last reviewed · How we verify
PF06700841
At a glance
| Generic name | PF06700841 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (PHASE3)
- A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis (PHASE2)
- Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease (PHASE2)
- A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (PHASE2)
- Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia (PHASE2)
- Renal Impairment Study of PF-06700841 (PHASE1)
- A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa (PHASE2)
- Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF06700841 CI brief — competitive landscape report
- PF06700841 updates RSS · CI watch RSS
- Pfizer portfolio CI